flow trial semaglutide nejm kidney outcomes 2024 hazard ratio 0.76 Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial flow trial semaglutide kidney outcomes

According to the World Health Organization, approximately 43 percent of adults are overweight and 16 percent are obese

GLP-1 medications make that assumption wrong almost every week

Contraindications: Patients with congestive heart failure, kidney disease, or fluid overload conditions should not receive IV therapy without specific medical oversight, as additional fluids can worsen these conditions

Its Too Expensive : Lets face it, GLP-1 medications like Zepbound and Wegovy are pricey, and insurance companies dont want to pay for it

Weekly injections that create a long, steady feeling of appetite control will feel different at the grocery store than a daily dose that causes sharper ups and downs in hunger

We administer Semaglutide as a once-weekly injection (in many cases) using a pre-filled pen, and the dose is gradually increased over time to find the level you tolerate best